Recipharm AB Market Research Report

Company Overview

Name and Core Mission

• Company Name: Recipharm AB

• Mission Statement: To provide experienced, global CDMO services dedicated to meeting evolving customer needs through operational excellence, scientific know-how, and customer connectivity. Recipharm is committed to sustainability, ensuring responsible and ethical behavior across their operations.

Company Foundation and Leadership

• Founded: 1995

• Founded by: Started with the management buyout of a solid dose facility in Stockholm.

• Key People:

• No specific current key people mentioned in the available data.

Headquarters and Global Presence

• Headquarters: Sweden

• Global Presence: Operations are spread across Europe, India, Israel, and North America, with activities in 9 countries and a reach over 100+ markets.

Workforce and Financials

• Number of Employees: 5,200

• Revenue: No information is available.

Recognition and Core Expertise

• Known For: Recipharm is recognized as one of the oldest and most experienced CDMOs worldwide, with particular strengths in drug product manufacturing and advanced therapy medicinal products (ATMPs).

Products

Core Product Offerings

1. Biologics Manufacturing and Development

• _Description_: Includes production of mRNA, lipid nanoparticles, plasmid DNA, viral vectors and live viruses, and microbiome live biotherapeutics.

• _Key Features_: Robust process development, scalable manufacturing, advanced tech transfer capabilities.

2. Solids & Others

• _Description_: Solutions for the development and manufacturing of oral delivery medicines.

• _Key Features_: Comprehensive formulation development and production scalability.

3. Sterile Fill & Finish

• _Description_: Sterile manufacturing and filling services for both biologics and small molecules.

• _Key Features_: Aseptic fill capabilities, lyophilisation, multiple container configurations, integrated particle control systems.

4. Control Drugs

• _Description_: Expertise in the formulation and manufacturing of substances with regulatory control.

• _Key Features_: Secure facilities, compliance with both non-GMP and GMP standards.

5. High Potency OSD Drugs

• _Description_: Manufacturing of oral solid dose drug products with highly potent active ingredients.

• _Key Features_: Specialized containment facilities, custom risk assessments, high flexibility in small volume operations.

Recent Developments

Strategic Investments and Partnerships

• New Developments:

• Recipharm announced strategic acquisitions to enhance biologic offerings under ReciBioPharm, by incorporating industry specialists like Arranta Bio, GenIbet, and Vibalogics.

• Launch of ReciPredict for revolutionizing drug product development and manufacturing.

• New Products or Features:

• No specific new product launches are detailed, but continuous advancement in gene therapy and ATMP services is evident.

• Advanced services offered under pacts with companies like Hongene Biotech and strategic collaborations with LenioBio.

• Partnerships and Alliances:

• Announced an exclusive strategic alliance with Exela.

• Partnership with Hongene Biotech to deliver comprehensive end-to-end CDMO services in gene editing.

Market Trends and Industry Insights

• _mRNA Lyophilisation_: Focused insight into stabilizing mRNA therapies for long-term use.

• _Viral Vector Production_: Advancements in AAV manufacturing to meet contemporary clinical demands.

---

No additional commentary is included beyond the essential company-focused insights.